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Michal Brylinski and Jeffrey Skolnick
Center for the Study of Systems Biology, School of Biology, Georgia Institute of Technology,
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Abstract
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Many drug candidates fail in clinical development due to their insufficient selectivity that may
cause undesired side effects. Therefore, modern drug discovery is routinely supported by
computational techniques, which can identify alternate molecular targets with a significant
potential for cross-reactivity. In particular, the development of highly selective kinase inhibitors is
complicated by the strong conservation of the ATP-binding site across the kinase family. In this
paper, we describe X-ReactKIN, a new machine learning approach that extends the modeling and
virtual screening of individual protein kinases to a system level in order to construct a crossreactivity virtual profile for the human kinome. To maximize the coverage of the kinome, XReactKIN relies solely on the predicted target structures and employs state-of-the-art modeling
techniques. Benchmark tests carried out against available selectivity data from high-throughput
kinase profiling experiments demonstrate that for almost 70% of the inhibitors, their alternate
molecular targets can be effectively identified in the human kinome with a high (>0.5) sensitivity
at the expense of a relatively low false positive rate (<0.5). Furthermore, in a case study, we
demonstrate how X-ReactKIN can support the development of selective inhibitors by optimizing
the selection of kinase targets for small-scale counter-screen experiments. The constructed crossreactivity profiles for the human kinome are freely available to the academic community at
http://cssb.biology.gatech.edu/kinomelhm/
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Introduction
The Human kinome, one of the largest families in the human proteome, comprises >500
genes 1. The pivotal function of kinases is the signal transduction through a reversible
phosphorylation of tyrosine, threonine and serine residues in other proteins 2, 3. The strong
implication of kinase activity in numerous disease states such as cancer 4, diabetes 5,
inflammation 6, multiple sclerosis 7, cardiovascular disease 8 and neurological dysfunctions
9 makes them very important drug targets. Consequently, there is a growing interest in the
development of novel compounds with kinase inhibition as their mode of action 10–12; this
has resulted in over a hundred of kinase crystal structures complexed with low-molecularweight inhibitors reported in the public domain 13.
Many therapeutic strategies have been developed to modulate kinase activity 14. The most
prevalent is kinase inhibition by targeting the catalytic site of kinases with ATP-competitive
inhibitors 15. The ATP-binding site provides a compelling environment for binding a
diverse range of organic molecules devised to compete with ATP, mostly by mimicking the
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binding interactions of the adenosine moiety 16. Indeed, ATP-binding pockets are the
primary target sites for the majority of the currently available kinase inhibitors 17. However,
the structural and chemical features of the ATP-binding site as well as the catalytic
mechanism are highly conserved across the kinase family, which significantly complicates
the development of kinase inhibitors with sufficient target selectivity.
To address this significant issue, a number of computational techniques have been
developed to support experimental efforts directed towards the development of selective
kinase inhibitors. Most employ various classification schemas for the kinase space with the
underlying assumption that kinases belonging to a common category have higher potential
to bind similar compounds, which may give rise to undesired cross-reactivity effects. The
most straightforward approach to the classification of kinases is based on the global
sequence or/and structure similarity. A comprehensive survey carried out for all available
kinase sequences classified them into 30 distinct families, with 19 of them covering nearly
98% of all sequences and representing seven general structural folds 18. Nevertheless, it has
been demonstrated that a high probability of being inhibited by the same groups of
compounds requires very high sequence identity thresholds, typically more than 50–60%
19–21. However, the average pairwise global sequence identity in the human kinome is
~25%; those kinase pairs with a sequence identity of 50–60% and less, might or might not
have similar pharmacological profiles.
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In that regard, alternative approaches are required. A new method was proposed to classify
the medicinally relevant kinase space based on structure-activity relationship, SAR, profiles
22. Results obtained for 38 crystal structures of protein kinases and available small molecule
inhibition data showed that the SAR-based dendograms differ significantly from the
sequence-based clustering for distantly homologous targets. Another approach exploits
structure comparison of kinases based on a feature-similarity matrix 23. This new metric is
well correlated with a pharmacological distance generated by comparing affinity fingerprints
constructed from experimental cross-reactivity profiles. An interesting study reported
recently employs the QSAR analysis of residue contributions to the kinase inhibition profile
24. Using various experimental data sets, binding profiles are constructed based on the
properties of 29 residues in the active site, which can be applied to predict binding
similarities for untested kinases. Other chemical/structure-based classifications of ATPbinding sites in protein kinases are based on target family landscapes constructed using
molecular interaction field analysis 25, exposed physicochemical properties of the active
sites calculated by Cavbase 26, geometric hashing algorithms 27 and binding site signatures
created from “hot spot” residues 28. These techniques have been shown to be relatively
successful in the identification of protein kinase binding sites known experimentally to bind
the same compound; however, they require high-resolution crystallographic structures of the
target kinase proteins, preferably complexed with inhibitors. As a consequence, the covered
kinase space remains incomplete because it is limited by the availability of experimentally
solved crystal structures; this corresponds to only about 20% of the human kinome.
This gap can be bridged by protein structure prediction, particularly comparative modeling
29, 30. Current state-of-the-art protein structure prediction approaches have reached the
level where they can construct protein models whose quality is often comparable to that of
low-resolution experimentally determined structures 31. Nevertheless, theoretically
predicted protein structures may still have significant structural inaccuracies in their ligand
binding regions 32, 33; this requires appropriate computational techniques that are different
from those applicable to the crystal structures and which can accommodate structural
distortions without significant loss in accuracy.
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In our previous study, we described the results of the first proteome-scale structure modeling
and virtual screening of the entire human kinome 34. Using a template-based modeling
procedure 35, 36, we constructed structural models for all kinase domains in humans.
Subsequently, we applied a structure/evolution-based approach 37 to precisely detect target
sites. These were then subject to large-scale virtual screening against a large collection of
commercially available compounds using a novel hierarchical approach that combines
ligand- and structure-based filters 38, 39. Retrospective benchmarks against several
commonly used ligand libraries demonstrate that predicted molecular interactions between
kinases and small ligands substantially overlap with available experimental data. In this
paper, we attempt to extend the modeling and virtual screening of individual protein kinases
to the system level in order to construct a cross-reactivity virtual profile for the entire human
kinome. To achieve this goal, we develop X-ReactKIN, a machine learning approach that
estimates the potential for cross-reactivity from sequence, structure and binding properties
of the ATP-binding sites in protein kinases. We validate the results against available
selectivity data from high-throughput kinase profiling experiments. Finally, we demonstrate
how X-ReactKIN can support the development of selective inhibitors by suggesting alternate
targets for small-scale counter-screen experiments. The constructed cross-reactivity profiles
for the human kinome are freely available to the academic community via a user-friendly
web interface that can be accessed from http://cssb.biology.gatech.edu/kinomelhm/
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Methods
X-ReactKIN overview
Here, we use the concept of kinase family virtual profiling and compute the complete map
of putative cross-interactions within the human kinome. We develop X-ReactKIN, a machine
learning approach that combines sequence, structure and ligand binding similarities of the
ATP-binding sites in protein kinases to estimate the potential for cross-interactions. We note
that these similarities are calculated using modeled protein structures and virtual screening
ranking. We train a Naive Bayes classifier on the available inhibitor selectivity data to
calculate a new probabilistic cross-reactivity score, called a CR-score. Based on the
estimated similarities expressed by the CR-score values, we construct a cross-reactivity
virtual profile that corresponds to the matrix of pairwise interactions within the complete
human kinase family. Below, we describe the scoring functions used to construct the crossreactivity probabilistic score, the details of the datasets and machine learning
implementation including training and validation protocols.
Sequence-based score
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For each kinase domain in the human proteome, we constructed its structural model using a
state-of-the-art template-based structure prediction approach. This procedure, described in
detail in 34, involves the identification of evolutionary related templates in the PDB 40
using the PROSPECTOR_3 threading algorithm 36, followed by structure refinement/
assembly by TASSER, a coarse-grained procedure guided by tertiary restraints extracted
from the template structures 35. Subsequently, modeled kinase structures were taken as
targets for the prediction of ATP-binding sites by FINDSITE, a structure/evolution-based
method that identifies ligand-binding sites based on binding site similarity among
superimposed groups of functionally and structurally related template structures 37. The
sequence-based score corresponds to the sequence identity (a fraction of identical residues)
of binding residues between two protein kinases calculated using FINDSITE identified
residues and structure alignments generated by TM-align 41.
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In addition to the sequence-based scoring function, we also use a more structure-oriented
measure of binding site similarity. Here, we employ a modified version of a PocketMatch
score, PM-score, developed to provide a normalized similarity metric for binding site
comparisons 42. PocketMatch applies a geometric hashing algorithm to Cα atoms and sidechain geometrical centers of ligand binding residues extracted from the crystal structures of
protein-ligand complexes. Each binding site is represented by a set of 90 predefined distance
bins, whose populations capture its shape and chemical features. The original PocketMatch
approach uses residues, one or more of whose atoms are within a distance of 4A from the
crystallographic ligand position 42. In our modified implementation, we use the consensus
binding residues identified by FINDSITE in modeled kinase structures to populate the hash
bins and calculate the PM-score.
Ligand-based score
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Next, we introduce a new measure of binding site similarity that uses virtual screening ranks
to calculate a chemical correlation. In the previous study, we carried out a large-scale virtual
screening experiment for the complete human kinome 34. Here, we use this data to calculate
the correlation between compound ranks obtained for two binding pockets. The chemical
correlation corresponds to the Kendall τ rank correlation coefficient 43 calculated for the
average top ranked set of 10,000 ZINC compounds 44 ranked for individual target sites of
the entire human kinome by structure-based virtual screening using Q-DockLHM 39, 45.
Details on the docking/screening protocol are given in 34. Retrospective benchmarks carried
out against several ligand libraries demonstrate that this collection of compounds is likely to
be significantly enriched in ATP-competitive kinase inhibitors 34. A high Kendall τ
indicates that the pockets not only exhibit specific binding affinity toward similar
compounds, but also do not bind similar ligands. This new measure based on the similarity
of virtual screening ranks complements sequence-and structure-based similarities between
binding pockets.
Bioassay data
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We use three publicly available bioassay datasets to train and validate X-ReactKIN: 28
commercially available compounds examined against a panel of 20 protein kinases
(Bioassay #1) 46, 38 kinase inhibitors assessed across a panel of 317 kinases representing
>60% of the predicted human kinome (Bioassay #2) 47 and 20 kinase inhibitors including
16 approved drugs or those in clinical development screened against a panel of 119 protein
kinases (Bioassay #3) 48. Bioassay #1 reports inhibitor potency as a percentage of kinase
activity with respect to that in control incubations at an ATP concentration of 0.1 mM.
Bioassays #2 and #3 use ATP site-dependent competition binding with each compound
screened against the kinase targets at a single concentration of 10 μM and the binding
efficacy reported in terms of quantitative dissociation constants, Kd. First, primary kinase
targets(one per compound)are selected based on the strongest inhibition (Bioassay #1) or the
lowest dissociation constant (Bioassays #2 and #3). Then, for each compound, we define
alternate targets as kinases whose activity was inhibited to ≤25% of the control for Bioassay
#1and those with Kd ≤10 μM for Bioassays #2 and #3. Remaining kinases are classified as
non-targets. In this study, we use only compounds with at least one alternate kinase target.
The list of compounds, primary target kinases and the number of alternate targets as well as
non-targets is provided in Supplementary Information, SI Table 1.
Activity-based SAR profiles
In addition to the bioassay data described above, we comparethe virtual profiles constructed
by X-ReactKIN to the experimentally derived activity-based SAR similarities on an
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orthogonal dataset of 577 diverse compounds screened across a panel of 203 protein kinases
21. Here, we use similarity scores expressed by a Tanimoto coefficient calculated for
binding affinity fingerprints generated using an affinity threshold of 10%. Similarly to the
CR-score values, kinase SAR similarity scores also range from 0(dissimilar)to 1(identical).
For each kinase target, we assess the quality of X-ReactKIN virtual profiles calculated
against the remaining kinases using the Pearson correlation coefficient between the SAR
similarities and the CR-score values.
Machine learning
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In X-ReactKIN, we use a Naive Bayes classifier to combine individual scoring functions:
sequence-, structure- and ligand-based into a single probabilistic score. A classical Naive
Bayes classification is based on estimating P(X|Y), the probability or probability density of a
qualitative attribute X given class Y. In our classifier, the real-value attributes are modeled
by a Gaussian distribution, i.e. the classifier first estimates a normal distribution for each
class by computing the mean and standard deviation of the training data in that class, which
is then used to estimate P(X|Y) during classification 49. For a given pair of protein kinases,
the probabilistic score from the classifier, called a CR-score, estimates the chances of the
cross-reactivity from sequence, structure and binding similarities. X-ReactKIN was validated
using the following leave-one-out procedure: In each round, one inhibitor and its close
analogs are removed from the dataset that consists of the bioassay data described above and
the classifier is trained on the remaining compounds. Here, we define a close analog as a
compound that has a Tanimo to coefficient calculated using SMILES strings ≥0.7 50. Then,
for the excluded inhibitor and its primary target, the kinase proteins are ranked by the
predicted CR-score, with the top-ranked kinases assumed to be alternate targets. We assess
the accuracy of the off-target identification by a receiver operating characteristic
(ROC)analysis with the CR-score used as a variable parameter. In addition to the standard
ROC curves, we also calculate their distribution-free confidence bounds 51.
Virtual map of kinase cross-reactivity
Finally, X-ReactKIN was re-trained on all bioassay data and the complete map of putative
cross-interactions within the human kinome was calculated. Moreover, we constructed a
statistical model by fitting the distribution of the random CR-score values to a Normal
Inverse Gaussian distribution 52 in order to calculate the associated p-values. The fitting
procedure was done in R 53 using the ghyp package. The virtual cross-reactivity map is
visualized using matrix2png 54, with the kinase proteins grouped according to the subfamily
classification and clustered by sequence identity using CLUTO 55.
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Results
X-ReactKIN validation
Here, we use the available selectivity data from high-throughput kinase profiling
experiments to train and validate X-ReactKIN in the off-target prediction. As described in the
Methods section, for each kinase inhibitor and the corresponding primary target, the
remaining kinases are assessed with respect to the estimated potential for cross-reactivity,
i.e. ability to bind similar compounds. The results of leave-one-out validation are presented
as a ROC plot in Figure 1. Encouragingly, in all cases the performance of X-ReactKIN is
better than random, with a true positive rate >0.5 and a false positive rate <0.5 for almost
70% of the benchmark inhibitors. Particularly the results obtained for Bioassay #2 are very
promising since this panel of kinases covers >60% of the human kinome 47. In addition,
individual ROC plots for six selected compounds that include approved drugs such as
Gleevec (imatinib), Iressa (gefitinib), Nexavar (sorafenib), Sprycel (dasatinib) and Tarceva
(erlotinib) are presented in Figure 2. In all cases, the cross-validated performance of XMol Pharm. Author manuscript; available in PMC 2011 December 6.
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ReactKIN is significantly better than random, with tight confidence bounds particularly for
dasatinib (Figure 2A), erlotinib (Figure 2B), motesanib (Figure 2E) and sorafenib (Figure
2F). The calculated cut-off points (displayed in Figure 2), which maximize the sensitivity
and specificity show that most of the cross-interacting kinases are identified at the expense
of a relatively low false positive rate; the true (false) positive rate is 0.75 (0.25), 0.51 (0.18),
0.60 (0.34), 0.63 (0.27), 0.80 (0.18) and 0.53 (0.11) for dasatinib, erlotinib, gefitinib,
imatinib, motesanib and sorafenib, respectively.
Human kinome cross-reactivity profile
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Encouraged by the satisfactory performance of X-ReactKIN in benchmark tests, we retrained the model on all bioassay data and constructed a complete map of putative crossreactions within the entire human kinome. The details on the trained classifier used in XReactKIN are provided in Supplementary Information, SI Table 2. In Figure 3, for the human
kinome, we compare the cross-interaction potential expressed by a sequence-based
classification (Figure 3A) to the CR-score based classification (Figure 3B). In both Figures
3A and B, the kinases are clustered using sequence identity and the resulting dendograms
are shown on the top of each plot. Comparing the sequence identity score to the CR-score,
we observe many off-diagonal interactions pointed out by high CR-values (Figure 3B, blue
spots). These non-trivial similarities, which are clearly the most interesting, indicate the
possibility to bind similar compounds by remotely related protein kinases that belong to
different groups. In particular, many potential cross-interactions are observed between
kinases that belong to AGC (containing PKA, PKC and PKG protein kinases), CAMK
(calcium/calmodulin-dependent protein kinases) and STE (the homologues of yeast Sterile
kinases) groups. We note that whereas the average pairwise sequence identity within these
groups is relatively high: 38%, 34% and 36%, respectively, the inter-group sequence identity
is notably lower: 29%, 26% and 26% for AGC/CAMK, AGC/STE and CAMK/STE,
respectively. Even lower average sequence identity is seen between the TK (tyrosine
kinases) group and those kinases that belong to AGC (23%), CAMK (24%) and CMGC
(22%). The functional similarities indicated by the high CR-score values between these
kinase proteinsare undetectable on the basis of the sequence similarity alone. We have also
constructed a statistical model for the CR-score distribution in order to assign statistical
significance values. Here, we use a Normal Inverse Gaussian distribution, which fits well to
the data; this is shown as histograms as well as a quantile-quantile plot in Supplementary
Information, SI Figure 1.
Comparison to SAR profiles
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For a subset of 203 protein kinases, activity-based SAR similarities have been previously
reported 21. These similarities were calculated directly from the experimental data obtained
by screening the target kinases against a diverse set of >500 compounds, intended to
represent kinase inhibitor chemical space. This large-scale kinase profiling provides an
orthogonal dataset to validate the potential for cross-reactivity predicted by X-ReactKIN. The
results are presented in Figure 4. The direct comparison of the similarity between pairs of
kinases according to the SAR profiles and the CR-score values isshown in Figure 4A. In
both cases, the joint inhibition of many of these kinase pairs is observed within the TK
subfamily. Moreover, good agreement between both approaches is seen for the STE
subfamily, for which many predicted cross-interactions with kinases that belong to other,
particularly AGC and CAMK, groups are confirmed experimentally. The distribution of the
Pearson correlation coefficients between SAR similarities and CR-score values calculated
for 203 kinase targets is presented in Figure 4B. This distribution is clearly shifted toward
high (>0.5) values, which indicate a good overlap between experimental SAR and virtual
CR-score profiles for the majority of kinase targets. The average Pearson correlation
coefficient calculated across this dataset is 0.53 ± 0.14. The qualitative agreement between
Mol Pharm. Author manuscript; available in PMC 2011 December 6.
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the activity-based SAR similarities and the CR-score profiles provides significant validation
of the X-ReactKIN approach.
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Below, in a case study, we present a simple application of the human kinome crossreactivity virtual profile constructed by X-ReactKIN to demonstrate how it can be used to
optimize the selection of kinase targets for small-scale selectivity counter-screens in kinase
inhibitor development.
Case study: Inhibitors of Lck
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2-Aminopyrimidine carbamates are a new class of compounds with potent and selective
inhibition of the leukocyte-specific protein tyrosine kinase, Lck. Structure-activity
relationship studies and extensive pharmacological tests carried out for a series of
substituted 2-aminopyrimidine carbamates identified 2,6-dimethylphenyl-2-((3,5bis(methyloxy)-4-((3-(4-methyl-1-piperazinyl)propyl)oxy) phenyl)amino)-4pyrimidinyl(2,4-bis(methyloxy)phenyl)carbamateas a potent inhibitor of Lck, with an IC50
of 0.6 nM (compound 43 in the original paper) 56. Subsequently, a counter-screen against
15 other kinases that belong to TK, CMGC and AGC groups was carried out in order to
characterize the selectivity profile of this compound. Here, we compare the experimental
inhibition data to the in silico profile of Lck and demonstrate that the map of putative crossinteractions within the human kinome constructed by X-ReactKIN can be used to suggest
alternate kinase targets for the selectivity counter-screens. Figure 5 shows the selectivity
profile for the pyrimidine carbamate inhibitor. Experimentally, this inhibitor was found to be
highly selective with regards to the non-binding of JAK3(Kin. Dom. 2), MET, JNK3, PKCt,
IGF1R and CDK2 (Figure 5A). With the exception of JAK3 (Kin. Dom. 2), the CR-score
values (p-values) between Lck and these kinases are statistically insignificant: 0.483
(3.46×10−2), 0.126 (7.03×10−1), 0.182 (4.36×10−1), 0.267 (1.96×10−1), 0.229 (2.81×10−1)
and 0.162 (5.23×10−1), respectively (Figure 5B). For another 8 kinase targets, the
experimental IC50 values are in the range of 100 nM −1 μM; here the CR-scores are higher
(~0.3, p-values ~0.1 or better), with p-values <0.05 for BTK (1.39×10−2) and JAK2 (Kin.
Dom. 2, 4.07×10−2). No selectivity was shown against SRC kinase, for which the CR-score
(p-value) is 0.961 (1.55×10−3).
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Furthermore, the map of putative cross-interactions reveals other similarities between e.g.
FGFR1 and TIE2 (CR-score=0.856, p-value=2.92×10−3), JAK2 (Kin. Dom. 2)and TIE2
(CR-score=0.663, p-value=9.96×10−3), BTK and ZAP70 (CR-score=0.544, pvalue=2.23×10−2), JNK3 and p38a (CR-score=0.532, p-value=2.43×10−2) or JAK3(Kin.
Dom. 2)and SYK (CR-score=0.603, p-value=1.49×10−2), which indicate a high probability
of inhibition by similar compounds. In fact, the joint inhibition of many of these kinase pairs
has been already confirmed experimentally. We note that none of this information was used
for the construction of the CR-score matrix; indeed we were unaware of the experimental
results until after the predictions were made and we did a literature search. For example, an
oral kinase inhibitor ACTB-1003 with multiple modes of action, targeting cancer mutations
via FGFR1 inhibition (IC50=6 nM)and angiogenesis through inhibition of VEGFR2 (2 nM)
and TIE2 (4 nM) has been recently reported 57. Several inhibitors (compounds 10, 11, 12,
13 and 14 in the original paper) were found to non-selectively inhibit JAK2 (TIE2) with the
percent of enzyme activity at 1μM concentration of 6 (35), 5 (0), 0 (1), 30 (1) and 27 (7),
respectively 58. Moreover, compound 7 in the original paper was found to be the most
selective against JAK2 and TIE2 (3% and 26%) across a panel of 59 recombinant serine/
threonine and tyrosine kinases. Many JNK3 inhibitors are known to also inhibit p38a; e.g.
two compounds with a nanomolar activity against JNK3 (IC50 of 7 and 1 nM) have been
reported as potent p38a inhibitors as well, with the IC50 of 0.2 and 4 nM, respectively 59.
Finally, in vitro enzymatic assays of the novel JAK3 inhibitor R348 showed potent
inhibition of JAK3-and SYK-dependent pathways 60.
Mol Pharm. Author manuscript; available in PMC 2011 December 6.
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Lck was also included in the large-scale assessment of the chemical coverage of the kinome
space using activity-based SAR profiles 21. In Figure 4B (inset), we compare the
experimentally derived SAR similarities to the CR-score values calculated against the
remaining 202 protein kinases used as targets in the high-throughput binding assay. Here,
the Pearson correlation coefficient between the SAR similarities and the CR-score values is
0.73. This high correlation additionally confirms the good agreement between the potential
for cross-reactivity predicted by X-ReactKIN and the experimentally observed joint
inhibition of protein kinases.
Of course, a high probability of inhibition by the same groups of compounds does not
preclude a successful design of selective inhibitors. Rather, it should support the counterscreen selectivity experiments by optimizing the selection of possible off-targets, whose
binding sites have the highest potential for cross-reactivity.

Discussion
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Many drug candidates fail in clinical development due to their poor pharmacokinetic
characteristics and because of intolerable adverse effects, which may sometimes originate in
their insufficient selectivity 61. The physicochemical similarity between highly conserved
ATP-binding sites in protein kinases, one of the most important drug targets, has rendered
the challenge of designing selective inhibitors difficult. Nevertheless, the discovery of
selective kinase inhibitors demonstrate that there is enough conformational and chemical
diversity in and around the active site that can be explored to design compounds with
sufficient selectivity 14, 15. Thus, particularly in the early stages of drug development, the
knowledge of alternate kinase targets with significant potential for cross-reactivity is critical.
One common strategy in inhibitor design involves differential lead optimization to increase
the selectivity toward a particular drug target; such efforts are typically oriented towards the
development of highly specific inhibitors acting on single protein kinases. Later on, with the
approval of multi-target inhibitors, such as imatinib, sunitinib or lapatinib, an alternate
strategy has emerged, where drug-resistance can be overcome by simultaneously targeting
multiple kinase pathways 62. Multikinase inhibitors with highly tuned selectivity profiles
are currently of particular interest in pharmaceutical research 63. The functional
classification of the entire human kinome is of paramount importance in the development of
both highly selective as well as selectively unselective novel inhibitors.
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Due to the sparse and non-uniformly distributed structural data 64, cross-interactions are still
poorly defined atthe kinome level. To maximize the coverage of kinase functional space, we
developed X-ReactKIN, a Chemical Systems Biology approachfor in silico cross-reactivity
profiling that does not require high-resolution structural data. X-ReactKIN employs a stateof-the-art protein structure prediction algorithm followed by the recently developed Ligand
Homology Modeling approach to model kinase-drug interactions 34. Subsequently, the
modeling of individual kinase members is now extended to construct a cross-reactivity
virtual profile for the entire human kinome. This proteome-wide analysis represents a
significant improvement over other methods, which are generally confined to highresolution structures solved by protein crystallography.
In addition to the traditional sequence and structure similarity measures, our method also
uses a novel type of the binding site comparison by means of virtual screening ranks. A high
correlation between ligand rankings for two binding sites, referred to as a chemical
correlation, indicates that these sites not only exhibit specific binding affinity toward similar
molecules, but also do not bind similar compounds. Here, the accuracy of ligand docking
and ranking is essential. Particularly, using predicted receptor structures requires reliable
docking techniques capable of dealing with structural inaccuracies in protein models. It has
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been demonstrated that even moderate structural distortions of the modeled binding pockets
drastically interfere with the ability of the all-atom docking approaches to identify correct
docking geometries and to rank ligands 39, 65. Our virtual screening protocol that provides
compound ranking for the estimation of the chemical correlation employs evolution-based
ligand docking 38 followed by low-resolution binding pose refinement 39, 45. Such a
docking/ranking procedure is well suited for virtual screening applications using modeled
receptor structures since it exhibits significant tolerance to receptor structure deformation
39.
Modern drug discovery is routinely supported by computational techniques, such as virtual
screening, which prioritize drug candidates and increase the hit rate by restricting screening
libraries to compounds that likely exhibit the desired bioactivity. At the system level, the
functional classification of the human kinome expands our understanding of the structural,
chemical and pharmacological aspects of the kinase space and provides a practical strategy
that should prove useful for the design of more selective therapeutics.
Availability
The cross-reactivity virtual profile of the human kinase space is available at
http://cssb.biology.gatech.edu/kinomelhm/
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

ROC plot for the prediction of kinase inhibitor cross-reactivity using X-ReactKIN.
Compounds from Bioassays #1, #2 and #3 are shown as dark gray circles, black triangles
and light gray squares, respectively.
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Figure 2.

Individual ROC plots for selected inhibitors: (A) dasatinib, (B) erlotinib, (C) gefitinib, (D)
imatinib, (E) motesanib and (F) sorafenib. In each graph, the solid black line, the gray area
and the dashed line show the ROC curve for the CR-score, its 95% confidence bounds and
the accuracy of a random classifier, respectively. The cut-off point that maximizes the
sensitivity and specificity is represented by a black triangle. Chemical structures of the
inhibitors are also displayed.
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Figure 3.
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Classification of the human kinome by X-ReactKIN: (A) sequence similarity matrix and (B)
cross-reactivity matrix. In both plots, kinase proteins are grouped according to the subfamily
classification displayed on both axes. Within each group, kinase members are clustered
using sequence identity and the resulting dendograms are shown on the top of each graph.
Color scale expressing the sequence similarity (A) as well as the potential cross-reactivity
(B) is displayed on the right.
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Figure 4.
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Comparison of the X-ReactKIN virtual profiles to the SAR similarities on a set of 203
protein kinases. (A) Similarity between pairs of kinases ordered according to the Sugen
phylogenetic tree (available at http://kinase.com). Upper right and lower left triangles
represent the CR-score values and SAR similarities, respectively. The color scale expressing
both similarities is displayed in the right corner. (B) Histogram of the distribution of the
Pearson correlation coefficients between SAR similarities and CR-score values calculated
for 203 kinase targets. Inset: Correlation between SAR similarities and CR-score values for
the leukocyte-specific protein tyrosine kinase, Lck.
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Figure 5.

Selectivity profile for the pyrimidine carbamate inhibitor reported in 56: (A) experimental
inhibition constant values in μM with the IC50≤1 μM (>1 μM) in turquoise (yellow); (B)
pairwise CR-score matrix for the tested kinases, CR-score scale is given at the bottom; (C)
chemical structure of the inhibitor. In B, kinase pairs with a pairwise sequence identity of
>60% are marked with an X.
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